America approves more effective flu vaccine

The U.S. Food and Drug Administration has approved the first influenza vaccine based on messenger RNA (mRNA) technology, specifically designed for adults aged 50 and older. Studies show that this new vaccine is approximately 27% more effective compared to traditional vaccines during the 2024/2025 respiratory virus season. This vaccine allows for a shorter strain selection period, enhancing the match between the immune response and circulating influenza strains, thereby increasing its potential effectiveness. The vaccine is expected to be available this fall, following approval by the advisory committee, despite initial delays caused by limited testing.

articleDetails.fontSize.sizeحجم النص

تنويه: هذا ملخص تم إنشاؤه بواسطة الذكاء الاصطناعي

عرض المقال بالكامل